The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Effect of Hydroxyurea on the Frequency of Painful Crises in Sickle Cell Anemia
Open accessAbstract
BACKGROUND: In a previous open-label study of hydroxyurea therapy, the synthesis of fetal hemoglobin increased in most patients with sickle cell anemia, with only mild myelotoxicity. By inhibiting sickling, increased levels of fetal hemoglobin might decrease the frequency of painful crises. METHODS: In a double-blind, randomized clinical trial, we tested the efficacy of hydroxyurea in reducing the frequency of painful crises in adults with a history of three or more such crises per year. The trial was stopped after a mean follow-up of 21 months. RESULTS: Among 148 men and 151 women studied at 21 clinics, the 152 patients assigned to hydroxyurea treatment had lower annual rates of crises than the 147 patients given placebo (median, 2.5 vs. 4.5 crises per year, P < 0.001). The median times to the first crisis (3.0 vs. 1.5 months, P = 0.01) and the second crisis (8.8 vs. 4.6 months, P < 0.001) were longer with hydroxyurea treatment. Fewer patients assigned to hydroxyurea had chest syndrome (25 vs. 51, P < 0.001), and fewer underwent transfusions (48 vs. 73, P = 0.001). At the end of the study, the doses of hydroxyurea ranged from 0 to 35 mg per kilogram of body weight per day. Treatment with hydroxyurea did not cause any important adverse effects. CONCLUSIONS: Hydroxyurea therapy can ameliorate the clinical course of sickle cell anemia in some adults with three or more painful crises per year. Maximal tolerated doses of hydroxyurea may not be necessary to achieve a therapeutic effect. The beneficial effects of hydroxyurea do not become manifest for several months, and its use must be carefully monitored. The long-term safety of hydroxyurea in patients with sickle cell anemia is uncertain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“inhibition of HbS polymerization with hydroxyurea reduces the incidence of ACS (205).”
From Pathophysiology of Sickle Cell Disease (2019) · cites this paper as [205]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“By inducing increased levels of HbF through mechanisms that include suppressing erythropoiesis, hydroxyurea was first associated with reduction of morbidity and mortality in adults.81,82”
From Fetal hemoglobin in sickle cell anemia (2020) · cites this paper as [81]
Experimental — accuracy not yet measuredIn the citing paper
“Administration of hydroxyurea has been shown to induce expression of HbF, which interferes with the polymerization of HbS (33).”
From Red Blood Cell Function and Dysfunction: Redox Regulation, Nitric Oxide Metabolism, Anemia (2017) · cites this paper as [33]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An introduction to probability theory and its applications
(1958) · Journal of the Franklin Institute · doi:10.1016/0016-0032(58)90688-4 · Cited by 29,621
Draper, N. R., & Smith, H. (2005) · Technometrics · doi:10.1198/tech.2005.s303 · Cited by 17,993
Practical Nonparametric Statistics (2nd ed).
Groeneveld, R. A., & Conover, W. J. (1981) · Journal of the American Statistical Association · doi:10.2307/2287607 · Cited by 1,869
Pain in Sickle Cell Disease: Rates and Risk Factors
Platt, O. S., Thorington, B. D., Brambilla, D. J., Milner, P. F., Rosse, W. F., Vichinsky, E., & Kinney, T. R. (1991) · New England Journal of Medicine · doi:10.1056/nejm199107043250103 · Cited by 1,546
Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia.
Platt, O., Orkin, S. H., Dover, G., Beardsley, G. P., Miller, B. A., & Nathan, D. G. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111464 · Cited by 532
Self-citationHydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia [see comments]
Charache, S., Dover, G. J., Moore, R. D., Eckert, S. V., Ballas, S., Koshy, M., Milner, P., Orringer, E., Phillips, G., & Platt, O. (1992) · Blood · doi:10.1182/blood.v79.10.2555.2555 · Cited by 438
Self-citation5-Azacytidine stimulates fetal hemoglobin synthesis in anemic baboons.
DeSimone, J., Heller, P., Hall, L., & Zwiers, D. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.14.4428 · Cited by 384
Hydroxyurea as an Inhibitor of Human Immunodeficiency Virus-Type 1 Replication
Lori, F., Malykh, A., Cara, A., Sun, D. K., Weinstein, J. N., Lisziewicz, J., & Gallo, R. C. (1994) · Science · doi:10.1126/science.7973634 · Cited by 317
Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia [see comments]
Charache, S., Dover, G. J., Moore, R. D., et al. (1992) · Blood · doi:10.1182/blood.v79.10.2555.bloodjournal79102555 · Cited by 301
Self-citationDover, G. J., Brusilow, S. W., & Charache, S. (1994) · Blood · doi:10.1182/blood.v84.1.339.bloodjournal841339 · Cited by 229
Self-citationLevels of Fetal Hemoglobin Necessary for Treatment of Sickle Cell Disease
Noguchi, C. T., Rodgers, G. P., Serjeant, G., & Schechter, A. N. (1988) · New England Journal of Medicine · doi:10.1056/nejm198801143180207 · Cited by 222
Treatment of Sickle Cell Anemia with Hydroxyurea and Erythropoietin
Goldberg, M. A., Brugnara, C., Dover, G. J., Schapira, L., Charache, S., & Bunn, H. F. (1990) · New England Journal of Medicine · doi:10.1056/nejm199008093230602 · Cited by 193
Self-citationEffect of hydroxyurea on the rheological properties of sickle erythrocytes in vivo
Ballas, S. K., Dover, G. J., & Charache, S. (1989) · American Journal of Hematology · doi:10.1002/ajh.2830320206 · Cited by 162
Self-citationWeinfeld, A., Swolin, B., & Westin, J. (1994) · European Journal Of Haematology · doi:10.1111/j.1600-0609.1994.tb01303.x · Cited by 161
Papayannopoulou, T., de Ron, A. T. T., Veith, R. W., Knitter, G. H., & Stamatoyannopoulos, G. (1984) · Science · doi:10.1126/science.6200940 · Cited by 116
Adragna, N., Fonseca, P., & Lauf, P. K. (1994) · Blood · doi:10.1182/blood.v83.2.553.553 · Cited by 100
A cautionary note regarding hydroxyurea in sickle cell disease
Vichinsky, E. P., & Lubin, B. H. (1994) · Blood · doi:10.1182/blood.v83.4.1124.1124 · Cited by 75
Orringer, E., Blythe, D., Johnson, A., Phillips, G. J., Dover, G. J., & Parker, J. (1991) · Blood · doi:10.1182/blood.v78.1.212.212 · Cited by 75
Self-citationHydroxyurea exposure alters mouse testicular kinetics and sperm chromatin structure
Evenson, D. P., & Jost, L. K. (1993) · Cell Proliferation · doi:10.1111/j.1365-2184.1993.tb00015.x · Cited by 67
Fetal Hemoglobin, Sickling, and Sickle Cell Disease
Charache, S. (1990) · Advances in Pediatrics · doi:10.1016/s0065-3101(24)00238-x · Cited by 64
Self-citationHydroxyurea treatment for chronic myeloid leukaemia during pregnancy
Jackson, N. M., Shukri, A., & Ali, K. (1993) · British Journal of Haematology · doi:10.1111/j.1365-2141.1993.tb08672.x · Cited by 52
Comparison of teratogenic effects of aspirin and hydroxyurea in the Fischer 344 and Wistar strains
DEPASS, L. R., & Weaver, E. V. (1982) · Journal of Toxicology and Environmental Health · doi:10.1080/15287398209530252 · Cited by 47
Veith, R. C., Papayannopoulou, T., Kurachi, S., & Stamatoyannopoulos, G. (1985) · Blood · doi:10.1182/blood.v66.2.456.456 · Cited by 46
The nature of the embryo-protective interaction of propyl gallate with hydroxyurea
DeSesso, J. M., & Goeringer, G. C. (1990) · Reproductive Toxicology · doi:10.1016/0890-6238(90)90009-k · Cited by 26
Treatment of severe β‐thalassemia (patients) with myleran
Liu, D., Liang, C., Zao‐hui, A., Pei-Chen, J., Chen, S., Rong‐xin, W., Li‐juan, L., He‐qian, J., Dan‐yu, Z., & You‐wen, H. (1990) · American Journal of Hematology · doi:10.1002/ajh.2830330110 · Cited by 23
Maze Learning by Adult Rats after Inhibition of Neuronal Multiplication in Utero
ADLARD, B. P. F., & Dobbing, J. (1975) · Pediatric Research · doi:10.1203/00006450-197503000-00006 · Cited by 19
Boivin, P. (1993) · PubMed · Cited by 17
Research works printed but not linked: 10
- Dover GJ, 1994, Blood, 84, 339, 10.1182/blood.V84.1.339.339 · DOI
- 1994, Blood, 84, 404a
- Kalbfleisch JD, Prentice RL. The stastistical analysis of failure time data. New York: John Wiley, 1980:1-20, 70-142.
- Ferm VH, 1966, Arch Pathol, 81, 174
- Weichselbaum RR, Hallahan DE, Chen GTY. Biological and physical basis to radiation oncology. In: Holland JF, Frei E III, Bast RC Jr, Kufe DW, Morton DL, Weichselbaum RR, eds. Cancer medicine. 3rd ed. Vol. 1. Philadelphia: Lea & Febiger, 1993:539-66.
- Chemotherapeutic agents. In: Holland JF, Frei E III, Bast RC Jr, Kufe DW, Morton DL, Weichselbaum RR, eds. Cancer medicine. 3rd ed. Vol. 1. Philadelphia: Lea & Febiger, 1993:698-814.
- Berk PD, Wasserman LR, Fruchtman SM, Goldberg JD. Treatment of polycythemia vera: a summary of clinical trials conducted by the Polycythemia Vera Study Group. In: Wasserman LR, Berk PD, berlin NI, eds. Polycythemia vera and the myeloproliferative disorders. Philadelphia: W.B. Saunders, 1995:166-94.
- Fruchtman SM, 1994, Blood, 84, 518a
- Boivin P, 1993, Nouv Rev Fr Hematol, 35, 491
- Triadou P, 1994, Nouv Rev Fr Hematol, 36, 367
Cited by
Sorted by citations
Rees, D. C., Williams, T. N., & Gladwin, M. T. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61029-x · Cited by 2,504
Adams, R. J., McKie, V. C., Hsu, L., Files, B., Vichinsky, E., Pegelow, C., Abboud, M., Gallagher, D., Kutlar, A., Nichols, F. T., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807023390102 · Cited by 1,866
Self-citationPiel, F. B., Steinberg, M. H., & Rees, D. C. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1510865 · Cited by 1,488
Management of Sickle Cell Disease: Summary of the 2014 Evidence-Based Report by Expert Panel Members
Yawn, B. P., Buchanan, G. R., Afenyi-Annan, A. N., Ballas, S. K., Hassell, K. L., James, A. H., Jordan, L., Lanzkron, S. M., Lottenberg, R., Savage, W. J., et al. (2014) · JAMA · doi:10.1001/jama.2014.10517 · Cited by 1,599
Kato, G. J., Piel, F. B., Reid, C. D., Gaston, M. H., Ohene-Frempong, K., Krishnamurti, L., Smith, W. R., Panepinto, J. A., Weatherall, D. J., Costa, F. F., et al. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.10 · Cited by 1,501
Metadata
- Authors
- Charache, S., Terrin, M. L., Moore, R. D., Dover, G. J., Barton, F. B., Eckert, S. V., McMahon, R. P., & Bonds, D. R.
- Affiliations
- Johns Hopkins University (US)
- Maryland Medical Research Institute (US)
- National Heart, Lung, and Blood Institute (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1995-05-18
- Volume
- 332
- Issue
- 20
- Pages
- 1317-1322
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2313541759
- Semantic Scholar
- 2c0939e2f6480b519903bb15870e5b894887e70d
- Cited by
- 2,340
- References
- 26
- Citations by year
- 2026: 67 · 2025: 97 · 2024: 77 · 2023: 88 · 2022: 95 · 2021: 92 · 2020: 80 · 2019: 78 · 2018: 85 · 2017: 104 · 2016: 114 · 2015: 101 · 2014: 82 · 2013: 79 · 2012: 73
- FWCI
- 34.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bristol-Myers Squibb
- National Institutes of Health (5u01hl045696-05)
- National Heart, Lung, and Blood Institute (UO1-HL 45696, UO1 HL 45692, U01HL045692)
- National Center for Research Resources (RR00046, M01RR000046)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Health Sciences › Medicine › Hematology › Blood groups and transfusion
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Keywords
- hydroxyurea, sickle cell disease, vaso-occlusive crisis, fetal hemoglobin, blood transfusion, myelosuppression, treatment efficacy, adverse effects
- MeSH terms
- Adult, Anemia, Sickle Cell, Double-Blind Method, Female, Follow-Up Studies, Humans, Hydroxyurea, Male, Pain
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
